Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rimegepant Provides Rapid and Sustained Relief to Migraineurs

Key clinical point: An orally dissolving tablet formulation of rimegepant is safe and effective.

Major finding: About 20% of patients who received rimegepant were pain-free at 2 hours, compared with 12% of controls.

Study details: A randomized, double-blind, phase 3 trial of 1,186 patients with migraine.

Disclosures: The study was supported by Biohaven, which is developing rimegepant. Several of the investigators are employees of Biohaven.

Citation:

Lipton RB et al. N Eng J Med. 2019 Jul 11; 381:142-9.